{Reference Type}: Journal Article
{Title}: The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.
{Author}: Eng NF;Bhardwaj N;Mulligan R;Diaz-Mitoma F;
{Journal}: Hum Vaccin Immunother
{Volume}: 9
{Issue}: 8
{Year}: Aug 2013
{Factor}: 4.526
{DOI}: 10.4161/hv.24715
{Abstract}: Hepatitis B (HBV) virus infects the liver, and upon chronic infection, can cause liver cirrhosis and hepatocellular carcinoma. Despite universal vaccination programs against the virus, HBV still affects over 2 billion people worldwide, with over 240 million developing a chronic infection. While current alum-adjuvanted vaccines have shown efficacy in promoting seroprotection in healthy adults, 5-10% of immune-competent populations fail to achieve long-lasting seroprotection from these formulations. Furthermore, a large proportion of immunocompromised patients fail to achieve seroprotective antibody titers after receiving these vaccines. A novel vaccine candidate, HEPLISAV™, uses immunostimulatory sequences (ISS), in its formulation that helps induce a robust humoral and cell mediated immunity against HBV. In Phase III clinical trials, HEPLISAV™ has been shown to elicit seroprotective antibody titers with fewer immunizations. Similar safety profiles are demonstrated when compared with current HBV vaccines. For these reasons, HEPLISAV™ is an attractive vaccine to combat this global disease.